Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.

Clinical trial NCT05624099 · RECRUITING

Trial details

NCT number: NCT05624099
Sponsor: Fujian Cancer Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Esophageal Neoplasms Esophageal Diseases Digestive System Neoplasms

Start date: 2023-08-01
Primary completion: 2025-12-01
Enrollment: 75

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.